Results 1 to 10 of about 2,721 (68)
Hepatitis B vaccine development and implementation
Human Vaccines and Immunotherapeutics, 2020 Vaccination against hepatitis B is the most effective strategy to control HBV infection. The first licensed hepatitis B vaccine was developed by the purification of hepatitis B surface antigen (HBsAg) from plasma of asymptomatic HBsAg carriers. Then, the
Yi-Hua Zhou, Hong Zhao, Xiaoying Zhou
exaly +2 more sources
Vaccines, 2022 Nasvac (HeberNasvac®) is a novel therapeutic vaccine for chronic hepatitis B (CHB). This product is a formulation of the core (HBcAg) and surface (HBsAg) antigens of the hepatitis B virus (HBV), administered by nasal and subcutaneous routes, in a ...
Julio Cesar Aguilar +2 more
doaj +1 more source
Nigerian Journal of Medicine, 2022 Background: Hepatitis B is a life-threatening viral infection that causes acute and chronic diseases of the liver. Hepatitis B infection is endemic in Nigeria with a national pooled prevalence rate of 9.5%.
Olusegun Elijah Elegbede +3 more
doaj +1 more source
Frontiers in Pediatrics, 2022 ObjectivesThe hepatitis B vaccine comprises hepatitis B surface antigen (HBsAg) produced by transgenic yeast cells. There are few serious adverse events (SAE) reports after Hepatitis B vaccination.MethodsThe authors searched the Chinese legal documents ...
Jinmiao Lu +3 more
doaj +1 more source
Vaccines, 2021 Evidence on the effectiveness of hepatitis B virus (HBV) infection screening and vaccination programs remains rare in China. We used a quasi-experimental method, propensity score matching, to evaluate the effects of a community-based HBV infection ...
Xinyao Liu +10 more
doaj +1 more source
Zdorovʹe Rebenka, 2021 Background. Viral hepatitis is still one of the important health problems all over the world today. Hepatitis B is a life-threatening liver infection that can cause chronic infections.
Feyza Gökben Kahveci +2 more
doaj +1 more source
PLoS ONE, 2022 Hepatitis B vaccine has contributed to the reduction in hepatitis B virus infections and chronic disease globally. Screening to establish extent of vaccine induced immune response and provision of booster dose are limited in most low-and-middle income ...
Moses Ocan +6 more
doaj +2 more sources
Nature Communications, 2022 The hepatitis B vaccine is recognised as the most effective approach in reducing hepatitis-B-related morbidity; vaccine-escape mutations are however capable of infecting vaccinated individuals. In this work, authors aim to establish a hepatitis B vaccine
Ayaka Washizaki +19 more
doaj +1 more source
Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil
Tropical Medicine and Infectious Disease, 2022 Transgender women (TGW) have limited access to affordable viral hepatitis testing, hepatitis B vaccination, and treatment. We aimed to estimate the prevalence of viral hepatitis A, B, and C, as well as to compare the adherence and immunogenicity of two ...
Lucila Pessuti Ferri +12 more
doaj +1 more source
Preventive Medicine Reports, 2019 Hepatitis A and B vaccine coverage is suboptimal in US adults, even among those at increased risk for infection, morbidity, or mortality. To understand where medical education and resources might enhance vaccine coverage, it is important to first ...
P.K. Ghaswalla +6 more
doaj +1 more source